ALCJ Share Price Performance
€2.62
0.58 (28.75%)
Price €2.62
Share Pricen/a
Crossject Société Anonyme Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
ALCJ Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Crossject Société Anonyme Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.21
- -215.50%
- -279.25%
- -1,848.9%
About ALCJ
- Founded
- 2001
- Employees
- 102
- CEO
- WebsiteView website
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was founded in 2001 and is based in Dijon, France.
